Furthermore, clinical evidence suggests that IL-6 represents a prognostic factor for overall survival and that its plasmatic level upregulation is associated with poor prognosis in BC, mainly in triple-negative BC, for which therapeutic approaches are scarce compared with the other subtypes [170,171,172,173]. This evidence concerns the gene IL6 and breast cancer.